Epstein-Barr Virus Nuclear Antigen 1 Recruits Cyclophilin A to Facilitate the Replication of Viral DNA Genome.
Epstein-Barr virus nuclear antigen 1
cyclophilin A
latent genome
pathogenesis
persistence
replication
Journal
Frontiers in microbiology
ISSN: 1664-302X
Titre abrégé: Front Microbiol
Pays: Switzerland
ID NLM: 101548977
Informations de publication
Date de publication:
2019
2019
Historique:
received:
06
08
2019
accepted:
28
11
2019
entrez:
11
1
2020
pubmed:
11
1
2020
medline:
11
1
2020
Statut:
epublish
Résumé
Epstein-Barr virus (EBV) nuclear antigen 1 (EBNA1)-mediated DNA episomal genome replication and persistence are essential for the viral pathogenesis. Cyclophilin A (CYPA) is upregulated in EBV-associated nasopharyngeal carcinoma (NPC) with unknown roles. In the present approach, cytosolic CYPA was found to be bound with EBNA1 into the nucleus. The amino acid 376-459 of the EBNA1 domain was important for the binding. CYPA depletion attenuated and ectopic CYPA expression improved EBNA1 expression in EBV-positive cells. The loss of viral copy number was also accelerated by CYPA consumption in daughter cells during culture passages. Mechanistically, CYPA mediated the connection of EBNA1 with oriP (origin of EBV DNA replication) and subsequent oriP transcription, which is a key step for the initiation of EBV genome replication. Moreover, CYPA overexpression markedly antagonized the connection of EBNA1 to Ubiquitin-specific protease 7 (USP7), which is a strong host barrier with a role of inhibiting EBV genome replication. The PPIase activity of CYPA was required for the promotion of oriP transcription and antagonism with USP7. The results revealed a strategy that EBV recruited a host factor to counteract the host defense, thus facilitating its own latent genome replication. This study provides a new insight into EBV pathogenesis and potential virus-targeted therapeutics in EBV-associated NPC, in which CYPA is upregulated at all stages.
Identifiants
pubmed: 31921057
doi: 10.3389/fmicb.2019.02879
pmc: PMC6923202
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2879Informations de copyright
Copyright © 2019 Xin, Du, Liu, Xie, Zuo, Yang, Hu, Yue, Zhang, Cao, Zhu and Lu.
Références
J Virol. 1996 Jun;70(6):3551-60
pubmed: 8648689
Asian Pac J Cancer Prev. 2013;14(1):367-72
pubmed: 23534755
J Virol. 2014 May;88(9):4736-43
pubmed: 24522922
PLoS One. 2012;7(2):e31063
pubmed: 22347431
Cancer Med. 2019 Jun;8(6):3142-3151
pubmed: 31063269
J Virol. 2012 Mar;86(6):3088-99
pubmed: 22205737
J Biol Chem. 2003 Nov 28;278(48):47753-61
pubmed: 14506283
J Virol Methods. 2011 Sep;176(1-2):103-7
pubmed: 21723326
Oncotarget. 2015 Dec 1;6(38):41033-44
pubmed: 26517512
Proc Natl Acad Sci U S A. 2016 Feb 23;113(8):2229-34
pubmed: 26858444
J Innate Immun. 2012;4(4):387-98
pubmed: 22433582
J Biol Chem. 2003 Aug 8;278(32):29987-94
pubmed: 12783858
Vaccines (Basel). 2015 Feb 05;3(1):74-89
pubmed: 26344947
Virol Sin. 2017 Jun;32(3):175-187
pubmed: 28669004
J Virol. 2018 Nov 12;92(23):
pubmed: 30209170
Oncogenesis. 2017 Dec 22;6(12):402
pubmed: 29284791
Chin J Cancer. 2014 Nov;33(11):527-8
pubmed: 25367333
Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):8245-50
pubmed: 9653172
J Virol. 1991 Jan;65(1):483-8
pubmed: 1845903
Virol J. 2010 Dec 30;7:372
pubmed: 21192783
Cancer Res. 2008 Sep 1;68(17):6997-7005
pubmed: 18757414
J Biol Chem. 2009 Jun 19;284(25):16998-7005
pubmed: 19380579
Int J Nanomedicine. 2015 Jan 30;10:903-21
pubmed: 25673987
J Innate Immun. 2017;9(6):574-586
pubmed: 28877527
Int J Cancer. 2008 Nov 1;123(9):2105-12
pubmed: 18688856
Chin J Cancer. 2014 Dec;33(12):581-90
pubmed: 25418193
Expert Rev Mol Med. 2015 Aug 18;17:e15
pubmed: 26282825
Virol Sin. 2017 Oct;32(5):349-356
pubmed: 29116589
Proc Natl Acad Sci U S A. 2014 Jan 7;111(1):243-8
pubmed: 24344309
Immunol Res. 2000;21(2-3):211-7
pubmed: 10852119
Lab Invest. 2014 Nov;94(11):1188-99
pubmed: 25068657
J Hepatol. 2014 Nov;61(5):1166-74
pubmed: 25048953
Gastroenterology. 2015 Feb;148(2):403-14.e7
pubmed: 25305505
Hepatology. 2009 Nov;50(5):1638-45
pubmed: 19821520
J Virol. 2012 Jun;86(12):6745-57
pubmed: 22514345
J Proteomics. 2014 Sep 23;109:162-75
pubmed: 24998431
Mol Cell Biol. 1985 Aug;5(8):1822-32
pubmed: 3018528
J Virol. 2017 Aug 10;91(17):
pubmed: 28637758
J Virol. 1997 Aug;71(8):5915-21
pubmed: 9223481
PLoS Biol. 2012;10(6):e1001351
pubmed: 22745600
Curr Opin Virol. 2012 Dec;2(6):733-9
pubmed: 23031715
J Gen Virol. 2003 Jul;84(Pt 7):1687-99
pubmed: 12810862
J Virol. 2011 Oct;85(19):10425-30
pubmed: 21795327
Scientifica (Cairo). 2012;2012:438204
pubmed: 24278697
Cancer Res. 2004 Aug 1;64(15):5251-60
pubmed: 15289331
Lab Invest. 2010 Feb;90(2):196-209
pubmed: 19997065
Cell. 1993 Jun 18;73(6):1067-78
pubmed: 8513493
J Virol. 2013 Jul;87(13):7777-80
pubmed: 23637409
Cancer Lett. 2016 Apr 28;374(1):22-30
pubmed: 26828135
Cancer Cell Int. 2012 Jul 04;12(1):19
pubmed: 22631225
Curr Opin Virol. 2013 Jun;3(3):227-32
pubmed: 23683686
Curr Top Microbiol Immunol. 2015;390(Pt 1):151-209
pubmed: 26424647
Sheng Li Xue Bao. 2015 Aug 25;67(4):393-400
pubmed: 26300251
Rev Med Virol. 2002 Nov-Dec;12(6):359-74
pubmed: 12410528
Int J Cancer. 2018 Dec 15;143(12):3209-3217
pubmed: 29971780
Cold Spring Harb Perspect Biol. 2013 Jan 01;5(1):a013029
pubmed: 23284049
Oncogene. 2003 Aug 11;22(33):5108-21
pubmed: 12910248
J Infect Dis. 2011 Nov;204 Suppl 3:S817-24
pubmed: 21987757
Mol Cell. 2005 Apr 1;18(1):25-36
pubmed: 15808506